CN114502532A - 磺基取代的联芳基类化合物或其盐及其制备方法和用途 - Google Patents

磺基取代的联芳基类化合物或其盐及其制备方法和用途 Download PDF

Info

Publication number
CN114502532A
CN114502532A CN202080069437.4A CN202080069437A CN114502532A CN 114502532 A CN114502532 A CN 114502532A CN 202080069437 A CN202080069437 A CN 202080069437A CN 114502532 A CN114502532 A CN 114502532A
Authority
CN
China
Prior art keywords
compound
optionally substituted
cancer
halogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080069437.4A
Other languages
English (en)
Inventor
程耀邦
黄亚飞
周娟
董志强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Huiqi Biomedical Technology Co ltd
Original Assignee
Shanghai Huiqi Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Huiqi Biomedical Technology Co ltd filed Critical Shanghai Huiqi Biomedical Technology Co ltd
Publication of CN114502532A publication Critical patent/CN114502532A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明涉及磺基取代的联芳基类衍生物化合物或其盐及其制备方法和用途，尤其涉及其中R1、R2、R3、R4、R5、R5’、R6、R7和X如说明书中所定义的式(I)化合物或者其立体异构体、互变异构体、稳定的同位素衍生物、药学上可接受的盐或溶剂合物，及其制备方法和含有它们的药物组合物，以及所述化合物在制备治疗或预防与RORγt有关的疾病的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202080069437.4A 2019-09-30 2020-09-29 磺基取代的联芳基类化合物或其盐及其制备方法和用途 Pending CN114502532A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910938067 2019-09-30
CN2019109380672 2019-09-30
CN202010966741 2020-09-15
CN2020109667410 2020-09-15
PCT/CN2020/118905 WO2021063362A1 (zh) 2019-09-30 2020-09-29 磺基取代的联芳基类化合物或其盐及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN114502532A true CN114502532A (zh) 2022-05-13

Family

ID=75337669

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011048206.3A Active CN112851557B (zh) 2019-09-30 2020-09-29 磺基取代的联芳基类化合物或其盐及其制备方法和用途
CN202080069437.4A Pending CN114502532A (zh) 2019-09-30 2020-09-29 磺基取代的联芳基类化合物或其盐及其制备方法和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202011048206.3A Active CN112851557B (zh) 2019-09-30 2020-09-29 磺基取代的联芳基类化合物或其盐及其制备方法和用途

Country Status (8)

Country Link
US (1) US20220402867A1 (zh)
EP (1) EP4039674A4 (zh)
JP (1) JP2022550489A (zh)
CN (2) CN112851557B (zh)
AU (1) AU2020360342A1 (zh)
CA (1) CA3155875A1 (zh)
TW (1) TW202126618A (zh)
WO (1) WO2021063362A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021228215A1 (zh) * 2020-05-15 2021-11-18 上海辉启生物医药科技有限公司 可用作RORγ调节剂的联芳基类化合物
CN111671909B (zh) * 2020-06-22 2022-06-21 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 他汀类药物联合ror激动剂在治疗结直肠癌方面的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505080A (ja) * 2004-07-01 2008-02-21 ニューヨーク ユニバーシティー ＲＯＲγｔ機能の調節のための組成物および方法
WO2013029338A1 (en) * 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
WO2015171558A2 (en) * 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
JP2018515491A (ja) * 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
CN107531679B (zh) * 2016-03-18 2021-07-02 江苏恒瑞医药股份有限公司 芳香酰胺类衍生物、其制备方法及其在医药上的应用
CN108863850B (zh) * 2017-02-09 2021-05-18 复旦大学 联芳基类化合物及其制备方法和用途
CA3068083A1 (en) * 2017-07-06 2019-01-10 Jiangsu Hengrui Medicine Co., Ltd. Indole-formamide derivative, preparation method therefor and use thereof in medicine

Also Published As

Publication number Publication date
TW202126618A (zh) 2021-07-16
CN112851557A (zh) 2021-05-28
CN112851557B (zh) 2022-06-10
CA3155875A1 (en) 2021-04-08
JP2022550489A (ja) 2022-12-01
EP4039674A4 (en) 2022-11-30
AU2020360342A1 (en) 2022-04-21
US20220402867A1 (en) 2022-12-22
WO2021063362A1 (zh) 2021-04-08
EP4039674A1 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
CN110016025B (zh) 一种免疫调节剂
WO2021175199A1 (zh) 一类芳香杂环类化合物及其在药物中的应用
JP6877407B2 (ja) Ｎｔｒｋ関連障害の治療に有用な化合物および組成物
JP2020509017A (ja) 新規イソインドリン誘導体、その医薬組成物および使用
WO2020011246A1 (zh) 含苯环的化合物、其制备方法及应用
WO2023098439A1 (zh) 一种吡唑衍生物，其制备方法和在药学上的应用
JP2021519828A (ja) ジアリール大員環化合物、医薬組成物及びその用途
CN112851557B (zh) 磺基取代的联芳基类化合物或其盐及其制备方法和用途
JP2022530936A (ja) ベンゾチオフェン化合物、その調製方法およびその使用
EP2350039A1 (en) Viral polymerase inhibitors
TW201917129A (zh) 含吡唑基的三并環類衍生物、其製備方法和應用
JP2021501215A (ja) アミノ置換窒素含有縮合環化合物、その調製方法及び使用
CN114206861A (zh) 用作ripk1抑制剂的稠环杂芳基化合物
CN112513041B (zh) 三环化合物
WO2022127779A1 (zh) 取代的哒嗪酮类化合物及其用途
CN109232358A (zh) 吲哚类衍生物或其盐及其制备方法和用途
WO2018145653A1 (zh) 联芳基类化合物及其制备方法和用途
WO2020200160A1 (zh) 一种含喹啉基化合物、药物组合物以及其用途
CN114269720A (zh) 乙酰辅酶a合成酶短链2(acss2)的小分子抑制剂
JP2021519825A (ja) 輸送体の調節薬としての二環式エノンカルボキシラートとその使用
WO2022116968A1 (zh) 一种新型n-杂环bet溴结构域抑制剂、其制备方法及医药用途
WO2021228215A1 (zh) 可用作RORγ调节剂的联芳基类化合物
WO2021228217A1 (zh) 可用作RORγ调节剂的苯胺类化合物
WO2021228216A1 (zh) 可用作RORγ调节剂的联芳基类化合物
WO2020098658A1 (zh) 20位取代的喜树碱衍生物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination